ICCC - ImmuCell Corporation

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
5.18
-0.04 (-0.77%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close5.22
Open5.02
Bid0.00 x 2200
Ask0.00 x 1100
Day's Range5.02 - 5.28
52 Week Range4.70 - 8.13
Volume27,017
Avg. Volume78,306
Market Cap37.06M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.19
Earnings DateFeb 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Thomson Reuters StreetEvents

    Edited Transcript of ICCC earnings conference call or presentation 19-Feb-20 2:00pm GMT

    Full Year 2019 ImmuCell Corp Earnings Call

  • GlobeNewswire

    ImmuCell Announces Correction to its Reported Unaudited Loss Per Share from ($0.06) to ($0.04) for the Quarter Ended December 31, 2019

    PORTLAND, Maine, Feb. 19, 2020 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire

    ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2019

    PORTLAND, Maine, Feb. 18, 2020 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire

    ImmuCell to Announce Preliminary Financial Results for the Year Ended December 31, 2019

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, will report unaudited financial results for the year ended December 31, 2019 after the market closes on Tuesday, February 18, 2020. The Company has scheduled a conference call on Wednesday, February 19, 2020 at 9:00 AM ET  to review the 2019 results. Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business and is available under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company.

  • Benzinga

    Why I Love Trading A Small Account, And Why You Should Too

    January is turning out to be a bit of a roller-coaster market for my main account. The last trade I took in the account on Wednesday in Neurotrope, Inc. (NASDAQ: NTRP) ended up netting me another $166 in the account.

  • Imagine Owning ImmuCell (NASDAQ:ICCC) And Wondering If The 32% Share Price Slide Is Justified
    Simply Wall St.

    Imagine Owning ImmuCell (NASDAQ:ICCC) And Wondering If The 32% Share Price Slide Is Justified

    Investors can approximate the average market return by buying an index fund. While individual stocks can be big...

  • GlobeNewswire

    ImmuCell Announces Preliminary, Unaudited Product Sales Results for the Year Ended December 31, 2019

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited product sales results for the year ended December 31, 2019. Total product sales increased by approximately $2,700,000, or 25%, to approximately $13,700,000 during the year ended December 31, 2019 versus the year ended December 31, 2018. Total product sales increased by approximately $695,000, or 24%, to approximately $3,600,000 during the fourth quarter ended December 31, 2019 versus the comparable period during 2018.

  • Thomson Reuters StreetEvents

    Edited Transcript of ICCC earnings conference call or presentation 11-Nov-19 9:30pm GMT

    Q3 2019 ImmuCell Corp Earnings Call

  • Hedge Funds Have Never Been More Bullish On ImmuCell Corporation (ICCC)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On ImmuCell Corporation (ICCC)

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and a 20% drop in […]

  • Is ImmuCell (NASDAQ:ICCC) Weighed On By Its Debt Load?
    Simply Wall St.

    Is ImmuCell (NASDAQ:ICCC) Weighed On By Its Debt Load?

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

  • Does ImmuCell Corporation (NASDAQ:ICCC) Have A Volatile Share Price?
    Simply Wall St.

    Does ImmuCell Corporation (NASDAQ:ICCC) Have A Volatile Share Price?

    If you own shares in ImmuCell Corporation (NASDAQ:ICCC) then it's worth thinking about how it contributes to the...

  • GlobeNewswire

    ImmuCell Announces Unaudited Financial Results for Third Quarter of 2019

    PORTLAND, Maine, Nov. 11, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire

    ImmuCell to Announce Unaudited Financial Results for Third Quarter of 2019

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle - will report unaudited financial results for the quarter ended September 30, 2019 after the market closes on Monday, November 11, 2019. The Company has scheduled a conference call that evening, Monday, November 11, 2019, at 4:30 PM ET to review the results. Interested parties can access the conference call scheduled by the Company to review these results by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 4:30 PM ET on Monday, November 11, 2019.

  • GlobeNewswire

    ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has entered into a lease covering approximately 14,300 square feet of office and warehouse space effective approximately November 1, 2019.

  • GlobeNewswire

    ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain™

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has entered into a new agreement with Norbrook Laboratories, Limited of Newry, Northern Ireland covering the formulation and aseptic filling of its Nisin Drug Substance into syringes for Re-Tain™, the Company’s novel treatment in development for subclinical mastitis in dairy cows. The new agreement (which replaces an expiring agreement) expires as of December 31, 2021 and allows for product ordered before the expiration date to be delivered into the early part of 2022.

  • Thomson Reuters StreetEvents

    Edited Transcript of ICCC earnings conference call or presentation 13-Aug-19 1:00pm GMT

    Q2 2019 ImmuCell Corp Earnings Call

  • GlobeNewswire

    ImmuCell Receives FDA Response To First CMC Submission for Re-Tain™

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle – today announced that it has received a response from the U.S. Food and Drug Administration (FDA) to its first phased Nisin Drug Substance submission of the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain™, the Company’s novel treatment in development for subclinical mastitis in lactating dairy cows.

  • GlobeNewswire

    ImmuCell Announces Unaudited Financial Results for Second Quarter of 2019

    PORTLAND, Maine, Aug. 12, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets.

  • Benzinga

    The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

    Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...

  • GlobeNewswire

    ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2019

    PORTLAND, Maine, Aug. 06, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets.

  • Thomson Reuters StreetEvents

    Edited Transcript of ICCC earnings conference call or presentation 14-May-19 1:00pm GMT

    Q1 2019 ImmuCell Corp Earnings Call

  • Benzinga

    The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 13) BioSig Technologies Inc (NASDAQ: BSGM ) Milestone Pharmaceuticals ...

  • GlobeNewswire

    ImmuCell Announces Unaudited Financial Results for First Quarter of 2019

    PORTLAND, Maine, May 13, 2019 -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and markets.

  • GlobeNewswire

    ImmuCell to Announce Unaudited Financial Results for First Quarter of 2019

    ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) - a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle - will report unaudited financial results for the quarter ended March 31, 2019 after the market closes on Monday, May 13, 2019.  The Company has scheduled a conference call the next day, Tuesday, May 14, 2019, at 9:00 AM ET to review the results. ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle.  ImmuCell markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef livestock, and is in the late stages of developing Re-Tain™, a novel treatment for mastitis, the most significant cause of economic loss to the dairy industry.  Press releases and other information about the Company are available at: http://www.immucell.com.

  • GlobeNewswire

    ImmuCell Corporation Announces Closing of $9 Million Public Offering of Common Stock

    ImmuCell Corporation (ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the closing of its previously announced underwritten public offering of 1,636,364 shares of common stock at a price to the public of $5.50 per share. All of the shares of common stock were offered by ImmuCell. The net proceeds from the offering are approximately $8.3 million, after deducting underwriting discounts and other estimated expenses incurred in connection with the offering.